Literature DB >> 16085917

Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge.

Darrilyn G Fraser1, Steve R Leib, Bao Shan Zhang, Robert H Mealey, Wendy C Brown, Travis C McGuire.   

Abstract

The effect of immunization with five lipopeptides, three containing T-helper (Th) epitopes and two with both Th and cytotoxic T-lymphocyte (CTL) epitopes, on equine infectious anemia virus (EIAV) challenge was evaluated. Peripheral blood mononuclear cells from EIAV lipopeptide-immunized horses had significant proliferative responses to Th peptides compared with those preimmunization, and the responses were attributed to significant responses to peptides Gag from positions 221 to 245 (Gag 221-245), Gag 250-269, and Pol 326-347; however, there were no consistent CTL responses. The significant proliferative responses in the EIAV lipopeptide-immunized horses allowed testing of the hypothesis that Th responses to immunization would enhance Th and CTL responses following EIAV challenge and lessen the viral load and the severity of clinical disease. The EIAV lipopeptide-immunized group did have a significant increase in proliferative responses to Th peptides 1 week after virus challenge, whereas the control group did not. Two weeks after challenge, a significant CTL response to virus-infected cell targets occurred in the EIAV lipopeptide-immunized group compared to that in the control group. These Th and CTL responses did not significantly alter either the number of viral RNA copies/ml or disease severity. Thus, lipopeptide-induced proliferative responses and enhanced Th and CTL responses early after virus challenge were unable to control challenge virus load and clinical disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16085917      PMCID: PMC1182189          DOI: 10.1128/CDLI.12.8.983-993.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  58 in total

Review 1.  Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.

Authors:  G B Fields; R L Noble
Journal:  Int J Pept Protein Res       Date:  1990-03

2.  Joint report of the Fourth International Workshop on Lymphocyte Alloantigens of the Horse, Lexington, Kentucky, 12-22 October 1985.

Authors: 
Journal:  Anim Genet       Date:  1987       Impact factor: 3.169

3.  The interaction of nominal antigen with T cell antigen receptors. I. Specific binding of multivalent nominal antigen to cytolytic T cell clones.

Authors:  R F Siliciano; A D Keegan; R Z Dintzis; H M Dintzis; H S Shin
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

4.  Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus.

Authors:  R C Montelaro; B Parekh; A Orrego; C J Issel
Journal:  J Biol Chem       Date:  1984-08-25       Impact factor: 5.157

Review 5.  Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture.

Authors:  P I Terasaki; D Bernoco; M S Park; G Ozturk; Y Iwaki
Journal:  Am J Clin Pathol       Date:  1978-02       Impact factor: 2.493

6.  Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs.

Authors:  Y Kono; K Hirasawa; Y Fukunaga; T Taniguchi
Journal:  Natl Inst Anim Health Q (Tokyo)       Date:  1976

7.  Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anaemia virus.

Authors:  K O'Rourke; L E Perryman; T C McGuire
Journal:  J Gen Virol       Date:  1988-03       Impact factor: 3.891

8.  Equine infectious anemia virus gag and pol genes: relatedness to visna and AIDS virus.

Authors:  R M Stephens; J W Casey; N R Rice
Journal:  Science       Date:  1986-02-07       Impact factor: 47.728

9.  Acute arthritis in caprine arthritis-encephalitis virus challenge exposure of vaccinated or persistently infected goats.

Authors:  T C McGuire; D S Adams; G C Johnson; P Klevjer-Anderson; D D Barbee; J R Gorham
Journal:  Am J Vet Res       Date:  1986-03       Impact factor: 1.156

10.  Transient suppression of equine immune responses by equine infectious anemia virus (EIAV).

Authors:  M J Newman; C J Issel; R E Truax; M D Powell; D W Horohov; R C Montelaro
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

View more
  6 in total

1.  Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Authors:  Tara L Tagmyer; Jodi K Craigo; Sheila J Cook; Deborah L Even; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

2.  Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route.

Authors:  R H Mealey; D M Stone; M T Hines; D C Alperin; M H Littke; S R Leib; S E Leach; S A Hines
Journal:  Vaccine       Date:  2007-08-15       Impact factor: 3.641

3.  Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen.

Authors:  Robert H Mealey; Steven R Leib; Matt H Littke; Bettina Wagner; David W Horohov; Travis C McGuire
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

4.  Bovine immune response to inoculation with Neospora caninum surface antigen SRS2 lipopeptides mimics immune response to infection with live parasites.

Authors:  Timothy V Baszler; Varda Shkap; Waithaka Mwangi; Christopher J Davies; Bruce A Mathison; Monica Mazuz; Dror Resnikov; Lea Fish; Benjamin Leibovitch; Lauren M Staska; Igor Savitsky
Journal:  Clin Vaccine Immunol       Date:  2008-02-27

5.  A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine.

Authors:  Qinglai Meng; Yuezhi Lin; Jian Ma; Yan Ma; Liping Zhao; Shenwei Li; Kai Yang; Jianhua Zhou; Rongxian Shen; Xiaoyan Zhang; Yiming Shao
Journal:  Viral Immunol       Date:  2012-11-21       Impact factor: 2.257

Review 6.  Targeting TLR2 for vaccine development.

Authors:  Afonso P Basto; Alexandre Leitão
Journal:  J Immunol Res       Date:  2014-06-26       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.